Figure 5.

Tumor Mutation-Specific Targeting of NRAS and HRAS Oncogenes in ERMS

(A) RAS tumor mutation-specific targeting strategy with locations of the mutation site (red bar) and targeting gRNAs (red arrows). The placement of the mutation-specific gRNAs is identified. (B) Cell viability after treatment of ERMS cells with RAS mutation-specific lentivirus. Data represent mean ± SEM of three biological replicates. (C) Sequencing analysis of the NRAS and HRAS target site after treatment of NRAS A183T and HRAS C181A mutant and non-mutant cells with tumor-specific targeting virus. ****p < 0.0001.